Inclusion Criteria:

• Patients aged 50 years or older.
• Patients with a clinical diagnosis of early stage Alzheimer's disease (NINCDS-ADRDA criteria) and with a Standardized Mini-Mental State Examination (MMSE) score of 20 - 26 inclusively and have demonstrated decline in their cognitive functions during the last six months as determined by the treating physicians.
• Patient has a score < 9 on the Hamilton Rating Scale for Depression (Ham-D) (Vida et al., 1994; Naarding et al., 2002). If on anti-depressant treatment the dose must have been stable for six months prior to study initiation.
• Patient is not taking fish oil or Omega 3/6 supplement 2 weeks before visit.
• Patient is living at home or in a home for elderly persons.
• Patient has a responsible caregiver who is able to provide information about the patient's functional status.
• Patients that require treatment with a cholinesterase inhibitor during the study follow up period will be continued in the study and will be treated with the study drug in combination with the cholinesterase inhibitors.
• Written informed consent is obtained from the patient or the legally accepted representative.

Exclusion Criteria:

• Severe or unstable diseases of any type, other than cognitive impairment, that may interfere with outcome evaluations. These include medical conditions expected to progress, recur, or change to such an extent that it may bias the assessment of the clinical or mental status of the patient to a significant degree or put the patient at special risk.
• Intake of fish oil or Omega 3/6 supplement other than the study drug
• Patients taking more than 400 mg vitamin E.
• The patient is not able to reliably take the study medication for the duration of the study (Patient compliance is < 80% after the 2-week run-in period).
• Patients with severe medical condition(s) that in the view of the treating physician prohibits participation in the study.
• Patients using any other investigational agent, or participating in another study within the last 30 days prior to the baseline visit.
• Patient with fish or seafood allergy
• Patient diagnosed with coagulopathy or on anticoagulant therapy